Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma (Nasdaq: MDCX) has advanced its SkinJect® treatment into registrational development for Gorlin Syndrome, a rare genetic disorder that causes recurring skin cancers and often requires …
Medicus Pharma Seeks FDA Path for Rare Skin Cancer Disorder Read More
DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) is expanding enrollment in a Phase 1 study of its experimental cancer drug APR-1051 after early clinical data showed tumor responses and disease …
Aprea Expands Cancer Trial After Early Tumor Responses Read More
RADNOR, PA — Mineralys Therapeutics (Nasdaq: MLYS) reported new Phase 3 data suggesting its experimental hypertension treatment lorundrostat may provide benefits for patients with chronic kidney disease, a finding that …
Mineralys Reports Kidney Disease Data Ahead of FDA Decision Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) reported new clinical and real-world data suggesting its liver disease drug Rezdiffra may reduce both cardiovascular and liver-related risk markers in patients with …
Madrigal Highlights Rezdiffra Data as MASH Market Expands Read More
WILMINGTON, DE — AstraZeneca said new Phase III cancer and rare disease data presented at the American Society of Clinical Oncology annual meeting could strengthen the company’s position in several …
AstraZeneca Highlights Late-Stage Cancer, Rare Disease Data at ASCO Read More
WAYNE, PA — Teleflex (NYSE: TFX) reported new clinical data supporting two of its urology products as the company prepares to divest its Interventional Urology business later this year, a …
Teleflex Reports New Data Ahead of Urology Unit Sale Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported new Phase 3 clinical trial data showing its experimental therapy molgramostim improved lung function and reduced disease-associated biomarkers in patients with autoimmune …
Savara Reports Phase 3 Biomarker Gains for Rare Lung Disease Read More LANGHORNE, PA — Savara (Nasdaq: SVRA) reported long-term Phase 3 trial data showing continued improvements in lung function and respiratory quality of life among patients receiving molgramostim for autoimmune pulmonary …
Savara Reports Long-Term Phase 3 Data Supporting Molgramostim Durability Read More
WASHINGTON, D.C. — The Department of Veterans Affairs is launching a clinical trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder, expanding federal research into …
VA Launches MDMA Trial for PTSD, Alcohol Use Disorders Read More LANGHORNE, PA — Savara (Nasdaq: SVRA) reported new Phase 3 clinical trial data showing patients treated with its experimental inhaled therapy molgramostim achieved greater improvements in exercise capacity than those …
Savara Reports Phase 3 Data Showing Exercise Gains in Rare Lung Disease Trial Read More